14T160: Abstracts: Vasculitis – ANCA-Associated II (2491–2496)

Presenting Author(s)

• SA

  Salem Almaani, MD, MS

  The Ohio State University Medical Center
  Columbus, OH, United States

  Disclosure(s): Amgen: Consultant (Ongoing); Aurinia: Consultant (Ongoing); Chemocentryx: Consultant (Terminated, January 1, 2023); Gilead: Grant/Research Support (Ongoing); Kezar: Consultant (Ongoing); Otsuka: Consultant (Terminated, April 1, 2023)
• HB

  Hulya Bukulmez, MD (she/her/hers)

  MetroHealth Medical Center, Case Western Reserve University
  Cleveland, OH, United States

  Disclosure information not submitted.
• 

  Rula A. Hajj-Ali, MD

  Cleveland Clinic
  Cleveland, OH, United States

  Disclosure(s): Amgen: Consultant (Terminated, March 13, 2023); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Terminated); UPTODATE: Royalties (Ongoing)
• TN

  Thomas Neumann, MD (he/him/his)

  Kantonsspital St. Gallen
  Rorschacherberg, Switzerland

  Disclosure information not submitted.
• MV

  Maxime Vignac, MSc

  Université Paris Cité
  Paris, France

  Disclosure information not submitted.
• ZW

  Zachary Wallace, MD, MSc

  Massachusetts General Hospital
  Newton, MA, United States

  Disclosure(s): No relevant disclosure to display

Abstract oral session.

Non-CME

Presentations:

• 2:00 PM – 2:10 PM PT

  Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort
  

  Presenting Author: Thomas Neumann, MD (he/him/his) – Kantonsspital St. Gallen
• 2:10 PM – 2:15 PM PT

  Q&A
  
• 2:15 PM – 2:25 PM PT

  The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life
  

  Presenting Author: Rula A. A. Hajj-Ali, MD – Cleveland Clinic
• 2:25 PM – 2:30 PM PT

  Q&A
  
• 2:30 PM – 2:40 PM PT

  Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis
  

  Presenting Author: Maxime Vignac, MSc – Université Paris Cité
• 2:40 PM – 2:45 PM PT

  Q&A
  
• 2:45 PM – 2:55 PM PT

  Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis
  

  Presenting Author: Salem Almaani, MD, MS – The Ohio State University Medical Center
• 2:55 PM – 3:00 PM PT

  Q&A
  
• 3:00 PM – 3:10 PM PT

  Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis
  

  Presenting Author: Zachary Wallace, MD, MSc – Massachusetts General Hospital
• 3:10 PM – 3:15 PM PT

  Q&A
  
• 3:15 PM – 3:25 PM PT

  HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression
  

  Presenting Author: Hulya Bukulmez, MD (she/her/hers) – MetroHealth Medical Center, Case Western Reserve University
• 3:25 PM – 3:30 PM PT

  Q&A